In a phase I/II study, Nussenblatt et al compared three immunosuppressive agents—daclizumab, rapamycin, and infliximab—in combination with anti‐VEGF therapy in AMD patients (Nussenblatt et al,2010). Here, VEGFA is linked to age-related macular degeneration.